Total submissions: 5
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| LDLR- |
RCV000211622 | SCV000294536 | likely pathogenic | Hypercholesterolemia, familial, 1 | 2016-03-25 | criteria provided, single submitter | literature only | |
| MGZ Medical Genetics Center | RCV000211622 | SCV002579490 | likely pathogenic | Hypercholesterolemia, familial, 1 | 2021-08-19 | criteria provided, single submitter | clinical testing | |
| Ambry Genetics | RCV002426990 | SCV002729352 | likely pathogenic | Cardiovascular phenotype | 2022-09-22 | criteria provided, single submitter | clinical testing | The p.C75Y variant (also known as c.224G>A), located in coding exon 3 of the LDLR gene, results from a G to A substitution at nucleotide position 224. The cysteine at codon 75 is replaced by tyrosine, an amino acid with highly dissimilar properties. Pathogenic LDLR mutations that result in the substitution or generation of cysteine residues within the cysteine-rich LDLR class A repeats and EGF-like domains are common in familial hypercholesterolemia (FH) (Villéger L. Hum Mutat. 2002;20(2):81-7). This alteration, which is also known as p.C54Y, has been reported in FH cohorts (Geisel J et al. Clin Chem Lab Med, 1998 May;36:279-82; Wang H et al. J Atheroscler Thromb, 2020 Dec;27:1288-1298). Internal structural analysis indicates this variant eliminates a disulfide bond critical for the structural integrity of the LDLR class A repeat 2 domain (Ambry internal data). Another alteration at the same codon, p.C75S (c.223T>A), has been described in a proband with a LDL-C level of 298mg/dL, in a Slovenian pediatric hypercholesterolemia cohort, and in additional probands referred for FH genetic testing (Emi M et al. Jpn Heart J. 1998;39(6):785-789; Klanar G et al. J. Am. Coll. Cardiol. 2015;66(11):1250-1257; Invitae pers.comm.). This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Based on the majority of available evidence to date, this variant is likely to be pathogenic. |
| Cardiovascular Genetics Laboratory, |
RCV000211622 | SCV000268542 | pathogenic | Hypercholesterolemia, familial, 1 | 2013-06-21 | no assertion criteria provided | clinical testing | |
| Laboratorium voor Moleculaire Diagnostiek Experimentele Vasculaire Geneeskunde, |
RCV000211622 | SCV000606043 | pathogenic | Hypercholesterolemia, familial, 1 | no assertion criteria provided | research |